Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab with carboplatin-paclitaxel with or without niraparib for recurrent or primary advanced endometrial cancer
NL-OMON59402Phase 3Active, not recruiting
- Sponsor
- TESARO, Inc.
- Start
- May 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab, niraparib, carboplatin and paclitaxel in endometrial cancer (EC) (4 arms), sponsored by TESARO, Inc. Primary endpoints: Progression-free survival and Overall survival. Started May 2020; status: active, not recruiting.
02
Drugs
dostarlimabniraparibcarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON59402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59402.